Literature DB >> 2060532

Clindamycin and primaquine as primary treatment for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS.

J R Black1, J Feinberg, R L Murphy, R J Fass, J Carey, F R Sattler.   

Abstract

The combination of clindamycin and primaquine was investigated as primary treatment for mild or moderately severe Pneumocystis carinii pneumonia (alveolar-arterial oxygen gradient less than 40 torr) in 36 AIDS patients. All patients were treated with primaquine 30 mg (base) orally for 21 days. The first 22 patients were treated with clindamycin 900 mg i.v. q8h for the first 10 days, followed by clindamycin 450 mg q6h orally for 11 days. Twenty of these 22 patients (91%) showed a marked clinical response by day 7. Four patients were later withdrawn from the study due to toxicity. An additional 14 patients were treated with an entirely oral regimen of clindamycin and primaquine. Thirteen of the 14 patients (93%) showed a marked therapeutic response and 12 (86%) successfully completed treatment. The combination of clindamycin and primaquine appears to be an effective and well-tolerated treatment for mild to moderately severe Pneumocystis carinii pneumonia in AIDS patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060532     DOI: 10.1007/bf01964465

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  3 in total

1.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

2.  Excretion, distribution, and metabolism of primaquine in rats.

Authors:  A M Clark; J K Baker; J D McChesney
Journal:  J Pharm Sci       Date:  1984-04       Impact factor: 3.534

3.  Antibiotic uptake by alveolar macrophages of smokers.

Authors:  W L Hand; R M Boozer; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

  3 in total
  7 in total

1.  Clinical and economic aspects of prophylaxis and treatment of Pneumocystis carinii pneumonia.

Authors:  K A Freedberg
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

Review 2.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

3.  Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies.

Authors:  P D Walzer; J Runck; S Orr; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

4.  8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; M Nasr; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 5.  Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection.

Authors:  B S Peters; E Carlin; R J Weston; S J Loveless; J Sweeney; J Weber; J Main
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

6.  Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.

Authors:  N P Dhammika Nanayakkara; Arba L Ager; Marilyn S Bartlett; Vanessa Yardley; Simon L Croft; Ikhlas A Khan; James D McChesney; Larry A Walker
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

7.  Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii.

Authors:  M S Bartlett; T D Edlind; M M Durkin; M M Shaw; S F Queener; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.